Arrowhead to Present at 2015 Barclays Global Healthcare Conference
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that
Arrowhead’s president and chief executive officer Christopher Anzalone,
Ph.D., will present at the 2015 Barclays Global Healthcare Conference on
March 11, 2015 at 1:35 p.m. EST. Investors may access live and archived
versions of the audio webcast of this presentation on the Company’s
website at http://ir.arrowheadresearch.com/events.cfm.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic
hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency, and partner-based programs in obesity and
oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadresearch.com/alerts.cfm.
Source: Arrowhead Research Corporation
Arrowhead Research Corporation
Vince Anzalone, CFA, 626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Todd James, 646-378-2926
ir@arrowres.com
or
Media:
Russo
Partners
Matt Middleman, M.D., 212-845-4272
matt.middleman@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media